2013/2017 H7N9 Prime-Boost Interval

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 21, 2018

Primary Completion Date

June 14, 2020

Study Completion Date

June 14, 2020

Conditions
Avian InfluenzaInfluenza Immunisation
Interventions
BIOLOGICAL

A/H7N9

Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).

DRUG

AS03

AS03 oil-in-water emulsion adjuvant.

BIOLOGICAL

Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013

Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).

OTHER

Phosphate Buffered Saline (PBS) diluent

Diluent for Influenza Virus Vaccine.

Trial Locations (6)

27704

Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham

30322-1014

Emory Children's Center - Pediatric Infectious Diseases, Atlanta

30030-1705

Emory Vaccine Center - The Hope Clinic, Decatur

52242-2600

University of Iowa - Vaccine Research and Education Unit, Iowa City

63104-1015

Saint Louis University - Center for Vaccine Development, St Louis

77030-3411

Baylor College of Medicine - Molecular Virology and Microbiology, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03589807 - 2013/2017 H7N9 Prime-Boost Interval | Biotech Hunter | Biotech Hunter